Clinical Trials Logo

Clinical Trial Summary

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.


Clinical Trial Description

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug or drug combination to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied. The names of the study drugs involved in this study are: - Nivolumab (OPDIVO) - Ipilimumab (YERYOY) This trial is studying whether nivolumab and ipilimumab work to treat INI1-negative cancers. The U.S. Food and Drug Administration (FDA) has not approved combination nivolumab and ipilimumab for the specific diseases in this study but it has been approved for other diseases. Nivolumab and ipilimumab have been tested in children to find out a safe dose of this combination. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04416568
Study type Interventional
Source Dana-Farber Cancer Institute
Contact Suzanne Forrest, MD
Phone (617) 632-6443
Email suzanne_forrest@dfci.harvard.edu
Status Recruiting
Phase Phase 2
Start date August 14, 2020
Completion date October 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT05286801 - Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Phase 1/Phase 2
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Active, not recruiting NCT03069378 - A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Phase 2
Completed NCT03837678 - Epithelioid Sarcoma Natural History Study
Active, not recruiting NCT02180867 - Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Phase 2/Phase 3
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Completed NCT02584309 - Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Not yet recruiting NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Phase 2
Completed NCT02601950 - A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Phase 2
Completed NCT03190174 - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Phase 1/Phase 2
Recruiting NCT03099681 - An Observational Study on Epithelioid Sarcoma
Recruiting NCT05407441 - Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Phase 1/Phase 2
Recruiting NCT03967834 - Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group N/A
No longer available NCT04225429 - Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma